河北医科大学学报

• 论著 • 上一篇    下一篇

奥西替尼联合颅脑放疗治疗非小细胞肺癌脑转移效果观察

  

  1. 1.河北省胸科医院肿瘤科，河北 石家庄 050041；2.河北省胸科医院妇产科，河北 石家庄 050041；
    3.河北省胸科医院放射科，河北 石家庄 050041
  • 出版日期:2020-06-25 发布日期:2020-06-29
  • 作者简介:侯志华（1981-），女，河北石家庄人，河北省胸科医院主治医师，医学硕士，从事肿瘤诊治研究。
  • 基金资助:
    河北省医学科学研究课题计划（20200028）

Observation of the therapeutic effect of oxitinib combined with craniocerebral radiotherapy on brain metastasis of lung cancer
 

  1. 1.Department of Oncology, Hebei Chest Hospital, Shijiazhuang 050041, China; 2.Department of
    Obstetrics and Gynecology, Hebei Chest Hospital, Shijiazhuang 050041, China; 3.Department of
    Radiology, Hebei Chest Hospital, Shijiazhuang 050041, China
  • Online:2020-06-25 Published:2020-06-29

HTML

PDF (PC)

150

摘要： 目的 奥西替尼联合颅脑放疗治疗非小细胞肺癌脑转移的价值和意义。
方法 选取非小细胞肺癌脑转移患者80例作为研究对象，应用计算机分组软件平均分组，单纯接受颅脑放射治疗患者40例设为对照组，奥西替尼联合颅脑放疗治疗患者40例设为试验组，比较2组患者临床疗效、颅内及颅外无进展生存期、血清癌胚抗原（carcinoembryonic antigen，CEA）和血管内皮生长因子（vascular endothelium growth factor，VEGF）表达水平。
结果 试验组临床疗效优于对照组，客观缓解率和疾病控制率高于对照组，颅内、颅外无进展生存期长于对照组（P＜0.05或P＜0.01）；治疗后，2组血清CEA、VEGF表达水平明显低于治疗前，试验组血清CEA、VEGF表达水平明显低于对照组（P＜0.01）。
结论 奥西替尼联合颅脑放疗治疗非小细胞肺癌脑转移，可以提高临床效率，降低CEA、VEGF表达水平，延长患者生存期，效果显著，值得临床使用。

关键词: 癌, 非小细胞肺, 肿瘤转移, 奥西替尼, 颅脑照射

Abstract: Objective To study the value and significance of oxitinib combined with radiotherapy in the treatment of brain metastasis of NSCLC.
Methods Eighty patients with brain metastasis from non-small cell lung cancer were selected as the study object. The computer software was used to divide the patients into two groups. 40 patients who only received craniocerebral radiation therapy were set as the control group, and 40 patients who received combination of oxitinib and craniocerebral radiation therapy were set as the experimental group. The clinical efficacy, intracranial and extracranial progression free survival period, the expression level of antigen, carcinoembryonic antigen(CEA) and vascular endothelium growth factor(VEGF) were compared between two groups.
Results The clinical effect of the experimental group was better than that of the control group, the objective remission rate and disease control rate were higher than that of the control group, and the intracranial and extracranial progression free survival period was longer than that of the control group(P＜0.05 or P＜0.01). After treatment, the expression level of CEA and VEGF between two groups was significantly lower than that before treatment, and the expression level of CEA and VEGF in the experimental group was significantly lower than that in the control group(P＜0.01).
Conclusion The treatment of brain metastasis of NSCLC with oxitinib combined with craniocerebral radiotherapy can improve the clinical efficiency, reduce the expression level of CEA and VEGF, and prolong the survival period of patients. The effect is significant, which is worthy of clinical use.

Key words: carcinoma, non-small-cell lung； neoplasm metastasis； oxytinib, cranial irradiation

版权所有 © 《河北医科大学学报》编辑部
本系统由北京玛格泰克科技发展有限公司设计开发